InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.25
(
0.20%
)
US TECH 100
18,957.20
(
-0.23%
)
Dow Jones
40,659.76
(
0.24%
)
Brent Oil
78.75
(
-0.11%
)
Bitcoin
58,549.13
(
-0.08%
)
Post# of 252904
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biotech jim

Send PM Follow Ignore
Followers 49
Posts 644
Boards Moderated 0
Alias Born 05/02/2011

biotech jim

Re: DewDiligence post# 141403

Monday, 05/07/2012 11:21:21 AM

Monday, May 07, 2012 11:21:21 AM

Post# of 252904
I say that the tofacitinib AdComm opinion to be positive by plurality as well. The immune safety issues can be in the label like the oncology risks for Humira et al. Will be interesting the view on the radiology results. Surely there was an FDA dialogue on this as well as with the efficacy endpoints.

BJ
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up